Summit Therapeutics Inc. SMMT
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -49.64% | -25.50% | 839.20% | 824.62% | 757.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.54% | 15.22% | 419.33% | 418.71% | 414.97% |
| Operating Income | 8.54% | -15.22% | -419.33% | -418.71% | -414.97% |
| Income Before Tax | 9.65% | -14.75% | -400.96% | -387.81% | -368.59% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 9.65% | -14.75% | -400.96% | -387.81% | -368.59% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9.65% | -14.75% | -400.96% | -387.81% | -368.59% |
| EBIT | 8.54% | -15.22% | -419.33% | -418.71% | -414.97% |
| EBITDA | 8.55% | -15.21% | -419.45% | -418.86% | -415.17% |
| EPS Basic | 13.95% | -11.11% | -384.71% | -369.70% | -348.63% |
| Normalized Basic EPS | 13.97% | -11.08% | -417.50% | -404.19% | -385.73% |
| EPS Diluted | 14.51% | -9.86% | -358.78% | -350.89% | -341.11% |
| Normalized Diluted EPS | 13.97% | -11.08% | -417.50% | -404.19% | -385.73% |
| Average Basic Shares Outstanding | 5.29% | 4.03% | 4.05% | 4.06% | 4.39% |
| Average Diluted Shares Outstanding | 5.29% | 4.03% | 4.05% | 4.06% | 4.39% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |